Adopting Biosimilars

Organon Biosimilars is here for you every step of the way

Deciding, implementing, and monitoring the adoption of a biosimilar can seem daunting, but Organon Biosimilars is here to help you identify the various steps involved.

Download these resources for help navigating considerations along the biosimilar adoption process at both the institutional and private practice level.

For institutions

Roadmap for health care professionals for considering, implementing, and monitoring biosimilar adoption in an institution.

For physicians

Roadmap for health care professionals for considering, implementing, and monitoring biosimilar adoption in a private practice setting.

What to consider for biosimilar organizational adoption

Biosimilars may offer health care system benefits^1,2

Increased competition

Reduced cost for payers

Spearheading implementation

Before adding any medicine onto formulary, nearly every organization relies on its pharmacy and therapeutics (P&T) committee to conduct a broad and detailed evaluation of the product, including biosimilars.

Key elements of biosimilar formulary review:

Biosimilar Formulary Review - Clinical Parameters

Clinical Parameters³

^•Indication, MOA, and dosing and administration
^•Clinical efficacy and safety
^•Immunogenicity

Biosimilar Formulary Review - Product Characteristics

Product Characteristics³

^•Nomenclature
^•Supply chain
^•Packaging/Labeling

Biosimilar Formulary Review - Considerations

Considerations³

^•Cost/Reimbursement
^•Pharmacovigilance
^•Patient/Provider education
^•Tracking and information system implications

What should health system pharmacists know about biosimilars?

Advocating for Biosimilars

Interactive educational resource for pharmacists exploring the potential value biosimilars may bring to the health care system.

Trusting Biosimilars

Interactive educational resource for pharmacists overviewing clinical considerations for biosimilars.

Championing Biosimilars

Interactive educational resource discussing the role health system pharmacists play in the successful implementation of biosimilars.

MOA, mechanism of action.

References: 1. US Food and Drug Administration. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s biosimilars action plan. July 18, 2018. Accessed April 5, 2021. https://www.fda.gov/news-events/press-announcements/remarks-fda-commissioner-scott-gottlieb-md-prepared-delivery-brookings-institution-release-fdas 2. US Food and Drug Administration. Biosimilars action plan: balancing innovation and competition. July 2018. Accessed April 5, 2021. https://www.fda.gov/media/114574/download 3. Ventola CL. Evaluation of biosimilars for formulary inclusion: factors for consideration by P&T committees. P&T. 2015;40(10):680–689.